Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High – Should You Buy?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) shares reached a new 52-week high during trading on Friday . The stock traded as high as $26.24 and last traded at $25.49, with a volume of 68174 shares. The stock had previously closed at $24.42.

Chugai Pharmaceutical Stock Up 4.4 %

The stock has a market cap of $83.89 billion, a PE ratio of 33.10 and a beta of 0.81. The company has a fifty day moving average price of $22.06 and a 200 day moving average price of $22.78.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, research analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.